Asciminib is indicated for the treatment of adult patients with:
Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs).
This indication is approved under accelerated approval based on major molecular response (MMR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Ph+ CML in CP with the T315I mutation.
from FDA,2021.10
What is asciminib and what is it used for?Asciminib is an anticancer medicine co···【more】
Release date:2026-04-24Recommended:16
What is asciminib and what is it used forAsciminib is an anticancer medicine con···【more】
Release date:2026-04-24Recommended:16
The recommended dosage of asciminib should be determined through comprehensive e···【more】
Release date:2026-03-31Recommended:45
Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic p···【more】
Release date:2026-01-06Recommended:64
1. PregnancyAccording to the results of animal studies and the mechanism of acti···【more】
Release date:2024-12-05Recommended:175